Keyphrases
Abdominal Skin
9%
After Surgery
9%
Average Risk
9%
BRAF mutation
9%
BRG1
9%
Carbon Ion Beam
13%
Carbon Ion Radiotherapy
100%
Cervical Cancer Patients
9%
Colorectal Cancer Screening
9%
Computed Tomography Images
11%
DNA Double-strand Breaks
14%
Dose Assessment
9%
Dosimetric Parameters
9%
Head-and-neck Cancer
9%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
9%
High-grade Prostate Cancer
9%
Hypofractionation
43%
Intensity-modulated Radiotherapy
19%
Intermediate-risk Prostate Cancer
9%
Interstitial Lung Disease
9%
Irradiation Technique
9%
Local Control Rate
11%
Localized Prostate Cancer
11%
Lung
12%
Lung Adenocarcinoma
19%
Lung Cancer
14%
Lymph Node Metastasis
10%
Molecular Mechanism
12%
Mucositis
11%
Non-small Cell Lung Cancer (NSCLC)
30%
Overall Survival Rate
20%
Passive Scattering
9%
Patient Selection
13%
Peripheral Non-small Cell Lung Cancer
9%
Prospective Phase II Study
9%
Prostate Cancer
27%
Radiotherapy
15%
Re-irradiation
9%
Relapse-free
10%
RET Fusion
9%
Sacral Promontory
9%
Screening Outcomes
9%
Small Intestine
19%
Stage I Lung Cancer
19%
Standardized Uptake Value
9%
Surface Model
9%
Synthetic Lethality
9%
Tomotherapy
9%
Tongue
9%
Tumor
25%
Medicine and Dentistry
Adverse Event
20%
Bladder Metastasis
9%
Cervical Cancer
19%
Cholinergic Receptor
6%
Common Iliac Lymph Nodes
9%
Cyberknife
7%
Cylindroma
9%
Difficult Airways
9%
Disease
7%
DNA Strand
5%
Drug Megadose
7%
Fluorodeoxyglucose
9%
Head and Neck Cancer
9%
Head and Neck Carcinoma
9%
Intensity Modulated Radiation Therapy
19%
Intubation
9%
Ion Therapy
70%
Lung
11%
Lung Adenocarcinoma
9%
Lung Cancer
29%
Lung Metastasis
7%
Lung Tumor
8%
Lymph Node Metastasis
11%
Malignant Neoplasm
7%
Mucositis
11%
Myasthenia gravis
6%
Nasolacrimal Duct Obstruction
9%
Neoplasm
30%
Non Small Cell Lung Cancer
19%
Observational Study
9%
Overall Survival
27%
Pelvis
9%
Positron Emission Tomography
9%
Primary Tumor
6%
Progression Free Survival
13%
Prospective Study
13%
Prostate Cancer
34%
Radiation Therapy
32%
Re-Irradiation
9%
Recurrent Disease
12%
Relative Biologic Effectiveness
17%
Retrospective Study
9%
Sacrum
9%
Squamous Cell Carcinoma
5%
Standardized Uptake Value
9%
Stereotactic Body Radiation Therapy
9%
Survival Rate
23%
Tongue
9%
Tracheal Intubation
6%
Tumor Recurrence
9%
